Urinary Kallikrein Excretion in Hypertensive Man

Relationships to Sodium intake and Sodium-Retaining Steroids

¹ Hypertension-Endocrine Branch, National Heart and Lung Institute, National Institutes of Health Bethesda, Maryland 20014

Urinary kallikrein excretion was measured by a radiochemical esterolytic assay in patients with essential hypertension or primary aldosteronism. Patients with essential hypertension excreted significantly less (P < 0.001) kallikrein than did normal subjects when they were allowed an ad libitum sodium intake or given 259 mEq sodium/day. When sodium intake was changed from ad libitum to 9 mEq/day, kallikrein excretion increased in the majority of patients with essential hypertension, but it remained significantly less (P < 0.001) than that in normal subjects; however, aldosterone excretion was similar in both groups. Fludrocortisone, 0.5 mg/day for 10 days, increased kallikrein excretion in three patients with essential hypertension. In patients with primary aldosteronism, mean kallikrein excretion was sevenfold higher (P < 0.001) than that in patients with essential hypertension; kallikrein excretion remained unchanged when dietary sodium was altered, but it was decreased by treatment with spironolactone. Mean kallikrein excretion in patients with primary aldosteronism was also significantly higher (P < 0.001) than that in a normotensive control population. The results show that kallikrein excretion reflects the effective level of circulating sodium-retaining steroid in patients with primary aldosteronism but suggest that it is relatively unresponsive to endogenous sodium-retaining steroid in patients with essential hypertension. The data raise the possibility that the kallikrein-kinin system is of pathogenetic significance in human hypertensive disease.

Accepted on August 11, 1974

This article has been cited by other articles:

				V. Griol-Charhbili, L. Sabbah, J. Colucci, M.-P. Vincent, V. Baudrie, D. Laude, J.-L. Elghozi, P. Bruneval, N. Picard, P. Meneton, et al. Tissue kallikrein deficiency and renovascular hypertension in the mouse Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2009; 296(5): R1385 - R1391. [Abstract] [Full Text] [PDF]

				A. Blanchard, M. Azizi, S. Peyrard, N. Stern, F. Alhenc-Gelas, P. Houillier, and X. Jeunemaitre Partial Human Genetic Deficiency in Tissue Kallikrein Activity and Renal Calcium Handling Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 320 - 325. [Abstract] [Full Text] [PDF]

				R. Slim, F. Torremocha, T. Moreau, A. Pizard, S. C. Hunt, A. Vuagnat, G. H. Williams, F. Gauthier, X. Jeunemaitre, and F. Alhenc-Gelas Loss-of-Function Polymorphism of the Human Kallikrein Gene with Reduced Urinary Kallikrein Activity J. Am. Soc. Nephrol., April 1, 2002; 13(4): 968 - 976. [Abstract] [Full Text] [PDF]

				G. M. Yousef and E. P. Diamandis The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease Endocr. Rev., April 1, 2001; 22(2): 184 - 204. [Abstract] [Full Text]

				I. Duka, E. Kintsurashvili, I. Gavras, C. Johns, M. Bresnahan, and H. Gavras Vasoactive Potential of the B1 Bradykinin Receptor in Normotension and Hypertension Circ. Res., February 16, 2001; 88(3): 275 - 281. [Abstract] [Full Text] [PDF]

				D. Wang, H. Yoshida, Q. Song, L. Chao, and J. Chao Enhanced renal function in bradykinin B2 receptor transgenic mice Am J Physiol Renal Physiol, March 1, 2000; 278(3): F484 - F491. [Abstract] [Full Text] [PDF]

				L. Jin, L. Chao, and J. Chao Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR Am J Physiol Renal Physiol, March 1, 1999; 276(3): F476 - F484. [Abstract] [Full Text] [PDF]

				U. Hilgenfeldt, T. Puschner, U. Riester, J. Finsterle, J. Hilgenfeldt, and E. Ritz Low-salt diet downregulates plasma but not tissue kallikrein-kinin system Am J Physiol Renal Physiol, July 1, 1998; 275(1): F88 - F93. [Abstract] [Full Text] [PDF]

				C. Wang, P. Ford, C. Chao, L. Chao, and J. Chao Effect of cyclosporin A on the expression of tissue kallikrein, kininogen, and bradykinin receptor in rat Am J Physiol Renal Physiol, November 1, 1997; 273(5): F783 - F789. [Abstract] [Full Text] [PDF]

				J. Chao and L. Chao Functional Analysis of Human Tissue Kallikrein in Transgenic Mouse Models Hypertension, March 1, 1996; 27(3): 491 - 494. [Abstract] [Full Text]

				K. Chen, X. Zhang, E. W. Dunham, and B. G. Zimmerman Kinin-Mediated Antihypertensive Effect of Captopril in Deoxycorticosterone Acetate–Salt Hypertension Hypertension, January 1, 1996; 27(1): 85 - 89. [Abstract] [Full Text]

				J.-x. Ma, Z. Yang, J. Chao, and L. Chao Intramuscular Delivery of Rat Kallikrein-binding Protein Gene Reverses Hypotension in Transgenic Mice Expressing Human Tissue Kallikrein J. Biol. Chem., January 6, 1995; 270(1): 451 - 455. [Abstract] [Full Text] [PDF]

				O. B. Holland, C. E. Gomez-Sanchez, L. Kuhnert, C. Poindexter, and C. Y. C. Pak Antihypertensive Comparison of Furosemide With Hydrochlorothiazide for Black Patients Arch Intern Med, September 1, 1979; 139(9): 1015 - 1021. [Abstract] [PDF]

				J. R. MITCHELL, A. A. TAYLOR, J. L. POOL, C. R. LAKE, D. E. ROLLINS, and F. C. BARTTER Renin-Aldosterone Profiling in Hypertension Ann Intern Med, November 1, 1977; 87(5): 596 - 612. [Abstract] [PDF]

				G. M. Yousef, A. Scorilas, K. Jung, L. K. Ashworth, and E. P. Diamandis Molecular Cloning of the Human Kallikrein 15 Gene (KLK15). UP-REGULATION IN PROSTATE CANCER J. Biol. Chem., January 5, 2001; 276(1): 53 - 61. [Abstract] [Full Text] [PDF]